- Home
- BLX vs ZYME Comparison
BLX vs ZYME Comparison
Compare BLX & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLX | ZYME |
|---|---|---|
| Founded | 1977 | 2003 |
| Country | Panama | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1997 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BLX | ZYME |
|---|---|---|
| Price | $54.05 | $29.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.90 |
| AVG Volume (30 Days) | 142.9K | ★ 656.0K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $18.36 | $183.10 |
| Revenue Next Year | $9.95 | N/A |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $38.41 | $13.60 |
| 52 Week High | $63.20 | $30.62 |
Technical Indicators
Market Signals| Indicator | BLX | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 66.96 |
| Support Level | $52.41 | $22.26 |
| Resistance Level | $55.30 | N/A |
| Average True Range (ATR) | 1.12 | 1.60 |
| MACD | 0.05 | 0.33 |
| Stochastic Oscillator | 31.51 | 85.51 |
Price Performance
Historical ComparisonAbout BLX Banco Latinoamericano de Comercio Exterior S.A.
Bladex Inc is a Panama-based bank focused on providing financial solutions to financial institutions and corporations throughout Panama.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.